Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.48 |
| ▸ | CA2 | P00918 | 11/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 9/20 | 0.35 |
| ▸ | CA9 | Q16790 | 8/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.35 |
| ▸ | CA5A | P35218 | 3/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890626 | 0.78 | ALDH1A1 (0.36) | CA12CA9CA14GRIA1CA7 | |
| SCHEMBL20988269 | 0.77 | CA1 (0.50) | CA1CA2PPARACA12CA9 | |
| SCHEMBL23866582 | 0.76 | MEN1 (0.36) | CA1CA2CA12CA9CA14 | |
| Ethylene SCHEMBL11862146 | 0.73 | CA2 (0.57) | CA1CA2PPARACA12CA9 | |
| SCHEMBL966015 | 0.73 | CA1 (0.50) | CA1CA2PPARACA12CA9 | |
| SCHEMBL6494923 | 0.73 | CA1 (0.31) | CA1CA2CA9GRIA1 | |
| SCHEMBL14200545 | 0.73 | CA2 (0.45) | CA1CA2PPARACA12CA9 | |
| SCHEMBL272858 | 0.72 | TDP1 (0.36) | — | |
| SCHEMBL292699 | 0.72 | — | — | |
| SCHEMBL3346860 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024100139-A1 | USE OF IFN-I ACTIVITY AS A BIOMARKER FOR TLR INHIBITOR TREATMENT | MERCK PATENT GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| US-20200316051-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-10246478-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2019-04-02 | — | — | US | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | CA1 4858/4885CA2 4408/4885PPARA 3050/4885 |
| US-10246478-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | CA1 4858/4885CA2 4408/4885PPARA 3050/4885 |
| US-20200316051-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CA1 2293/4885CA2 4469/4885PPARA 308/4885 |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CA1 4822/4885CA2 4588/4885PPARA 213/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | CA1 3378/4885CA2 2487/4885PPARA 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.